Profile data is unavailable for this security.
About the company
Altrazeal Life Sciences Inc., formerly ULURU Inc., is engaged in offering advanced topical solutions. The Company is a specialty medical technology company that is involved in developing and commercializing wound care and drug delivery systems based on its patented technologies. Its patented technology platforms include Altrazeal and OraDisc. Altrazeal is a new class of material designed to optimize the wound bed environment and accelerate healing. When applied to a moist wound, the powder interacts with the wound exudate and hydrates. OraDisc is a water-erodible pharmaceutical carrier device, the multi-layered device may be applied to mucosal surfaces, and adheres immediately, delivering actives to treat specific localized diseases/disorders. OraDisc technology can deliver drugs systemically across the mucosal surface or for the release of drugs into the oral cavity. The device causes minimum discomfort and provides erosion rates to deliver therapeutics over different time intervals.
- Revenue in USD (TTM)568.75k
- Net income in USD-2.20m
- Incorporated1987
- Employees7.00
- LocationAltrazeal Life Sciences Inc4410 Beltway DrADDISON 75001United StatesUSA
- Phone+1 (214) 905-5145
- Fax+1 (214) 905-5130
- Websitehttps://www.uluruinc.info/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Refocus Group Inc | 0.00 | -4.77m | 20.00 | 4.00 | -- | -- | -- | -- | -0.1961 | -0.1961 | 0.00 | 0.0574 | 0.00 | 0.00 | -- | 0.00 | -140.63 | -- | -205.65 | -- | -- | -- | -- | -- | 3.08 | -44.01 | 0.00 | -- | -- | -- | 32.59 | -- | -- | -- |
| Altrazeal Life Sciences Inc | 568.75k | -2.20m | 20.00 | 7.00 | -- | 0.00 | -- | 0.00004 | -0.1093 | -0.1093 | 0.0282 | 0.2154 | 0.0689 | 0.3993 | 3.38 | -- | -26.67 | -45.42 | -36.70 | -77.20 | 67.69 | 62.08 | -387.26 | -423.73 | 1.29 | -3.56 | 0.1618 | -- | 62.04 | 14.12 | 56.52 | -- | -44.14 | -- |
| Tetralogic Pharmaceuticals Corp | 0.00 | -40.72m | 20.00 | 29.00 | -- | -- | -- | -- | -1.64 | -1.64 | 0.00 | -1.25 | 0.00 | -- | -- | 0.00 | -59.95 | -- | -69.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.28 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Lupus alpha Asset Management AGas of 30 Jun 2023 | 50.00k | 0.00% |
